The Invisible Layer Between Patients and Their Bills
When a patient receives a hospital bill, the number on the page is rarely the product of the hospital alone. Tucked between insurers, providers, and patients sits a sprawling network of billing intermediaries – revenue cycle management firms, third-party administrators, and claims processors – that shape what gets charged, what gets paid, and what gets disputed. For years, this layer operated largely outside public view. That is changing fast.
A growing coalition of state attorneys general has begun investigating whether these middlemen inflate costs, suppress claims, or engage in billing practices that harm both patients and state Medicaid programs. The scrutiny follows a pattern seen in other sectors where concentrated intermediary power quietly drives up prices without obvious accountability – and where the financial incentives of the middleman diverge sharply from the interests of the people the system is supposed to serve.
What These Companies Actually Do
Revenue cycle management firms handle the administrative machinery of hospital billing: coding diagnoses, submitting claims, appealing denials, and collecting payments. Hospitals outsource these functions because the work is complex, compliance-heavy, and expensive to run in-house. The firms that do this work are often paid as a percentage of collections – meaning their revenue rises when they collect more, not necessarily when they collect accurately or fairly.
That payment structure creates a tension worth examining. A firm compensated on a percentage of recoveries has a financial incentive to maximize what comes in, which can mean aggressive upcoding – assigning billing codes that reflect a more expensive service than what was actually provided – or pursuing patients for balances they may not legally owe. Neither practice is universally common, but investigators in multiple states are looking at whether certain firms have made them systematic.
Third-party administrators occupy a related but distinct role. They manage benefits programs for self-insured employers and government entities, processing claims and setting payment rates. Some have been accused of manipulating network arrangements to steer payments in ways that benefit the administrator rather than the plan. A few state-level investigations have zeroed in specifically on how these firms handle Medicaid-adjacent programs, where state funds are directly at stake.
Why State AGs Are Moving Now
Federal oversight of healthcare billing has been inconsistent, and several large enforcement gaps remain open. State attorneys general have constitutional authority over consumer protection and Medicaid fraud within their borders, which gives them a distinct lane to pursue cases that federal regulators have not prioritized. Several AGs have also benefited from recent federal False Claims Act amendments that make it easier to bring parallel state actions when Medicaid dollars are involved.
The timing also reflects an increase in patient complaints. As high-deductible health plans became more common, more patients began receiving direct bills – and scrutinizing them. Billing errors, duplicate charges, and unexpected balance bills have become a visible political issue in enough states that AGs now treat healthcare billing enforcement as both legally viable and electorally useful.
The Financial Stakes for Hospitals and Middlemen
Revenue cycle management is a multi-billion dollar industry, and the largest players handle billing for hospital systems that collectively treat millions of patients annually. When an AG investigation targets a firm of that scale, the financial exposure can be enormous. False Claims Act cases involving Medicaid overbilling have historically produced some of the largest healthcare settlements on record, and state-level equivalents carry similar penalty structures.
For the hospitals that contract with these firms, the legal risk is not entirely separate. Several investigations have sought to establish joint liability – arguing that a hospital cannot fully outsource responsibility for its own billing. That argument has found some traction in court. A hospital that handed off its entire revenue cycle operation to a third party and claimed ignorance of systematic upcoding is likely to face skepticism from both judges and juries.
The intermediary firms themselves are responding in predictable ways: hiring former regulators, restructuring contracts to shift liability back to provider clients, and lobbying state legislatures for clearer safe-harbor protections. Some are also pushing for federal preemption arguments, contending that state enforcement creates a patchwork of conflicting standards that makes national operations legally untenable. Whether that argument gains traction depends partly on whether Congress shows any appetite for federal billing oversight reform – which, so far, it has not.
This connects to a broader economic pressure on healthcare administration. Hospitals facing thin margins have leaned heavily on outsourced billing to protect revenue, creating deep financial dependence on the very firms now under investigation. Cutting ties with a large revenue cycle vendor mid-contract is expensive and operationally disruptive, which means many hospital systems are simultaneously cooperating with investigators and hoping the firms they rely on survive the scrutiny intact. That conflict of interest is not hypothetical – it is structurally embedded in how the industry is organized, and no one has proposed a clean way out of it.
Several states are also examining whether billing intermediaries have exploited gaps in price transparency laws. Federal rules passed in recent years require hospitals to publish their chargemasters and negotiated rates, but those disclosures do not capture what happens after the initial bill is generated – the adjustments, write-offs, and collection strategies managed by outside vendors. A patient looking at a hospital’s published prices is seeing only the front end of a process that continues long after discharge, largely invisible and almost entirely unregulated at the point where it matters most to the patient’s actual financial exposure.
